Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 10, 2024
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update.
